FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2979667084> ?p ?o ?g. }

• W2979667084 endingPage "746" @default.
• W2979667084 startingPage "746" @default.
• W2979667084 abstract "Abstract Abstract 746 Introduction: Primary systemic amyloidosis (AL) is a monoclonal plasma cell disorder associated with progressive organ dysfunction and short survival. Standard therapy for patients (pts) not eligible for autologous stem cell transplant (ASCT) is melphalan (Mel; M) + dexamethasone (Dex; D). With non-ASCT therapy, the median overall survival (OS) of high-risk AL pts remains < 1 yr. After the VISTA study showed the addition of bortezomib (Bz) to Mel + Prednisone improved response rate, complete response rate, response duration, and OS in pts with myeloma, we designed this study to determine if adding Bz to MD improves outcomes in AL. Key eligibility criteria: ECOG PS ≤ 3, Cr ≤ 5 mg/dL, T.Bili ≤ 2.5 x IULN, ALT/AST ≤ 3 x IULN, ANC ≥ 1.0 K/mm3, PLT ≥ 80 K/mm3, peripheral neuropathy (PN) ≤ Gr 2 (≤ 1 if painful), no lower limit for LVEF. Study design: Two-stage Phase II study. Stage I: 16 pts with biopsy-proven AL or light chain deposition disease (LCDD). 1° endpoint: complete hematologic responses (cHR). If ≥5 cHRs observed, then 2nd stage with 17 more pts to be opened. The study has a 90% power to detect a true cHR rate of 50%. 2° endpoints include overall HR (cHR + Partial Responses (PR)), organ response (OrR), and OS. Treatment: M (9 mg/m2 PO days 1-4; 6 mg/m2 if Cr > 2.5 mg/dL), Bz (1.3 mg/m2 IV days 1, 8, 15, 22; 1.0 mg/m2 if pt has PN at baseline) and D (40 mg PO/IV days of & days after Bz; 20 mg if ≥ 70 yrs, peripheral edema, or CHF) in 4-6 wk cycles, max of 20 cycles. PN was assessed serially with the FACT/GOG-Ntx survey. Results: To date, 23 pts have been enrolled: 21 with AL; 2 with LCDD. Med age 64 (range: 47-76). Med # prior Rx: 1 (range: 0-2; 7 with ≥1 prior ASCT). Med # organs involved: 4 (range 1-6; 8 pts with ≥ 3). PS 0-1/2-3: 18/1. Response data for the 16 pts comprising stage 1 of this two-stage study are reported here; accrual of all 33 pts is expected to be complete by ASH, and results will be updated. One pt who was not response-evaluable (RE) for HR is included in toxicity data (n=17). Med # cycles MD-Bz: 4+ (range: 2-12+; 9 pts still on treatment). 15 of 16 pts had heme responses: 6 cHRs & 9 PRs. Ten RE pts had OrR (2 cardiac, 3 renal, 6 nerve, 1 lung; total >10 because some pts improved in > 1 organ). Nerve symptom improvement occurred exclusively in pts with cHR. Two pts had progressive disease (PD). Two pts died (4.5 and 9 mos from enrollment, from pneumonia and PD, respectively). Despite baseline dose adjustment for co-morbidities, 12 pts needed subsequent dose-reduction of ≥ 1 of the study meds during therapy (10 Bz, for thrombocytopenia and/or PN in almost all cases). Five pts developed neutropenia (Gr 3-4: 1), 15 pts developed thrombocytopenia (Gr 3-4: 11). Nine pts developed peripheral neuropathy (Gr 3: 2). Other grade 3-4 non-hematologic AEs seen in ≥ 2 pts included edema (5), syncope (3), SVT (2), dehydration (2), fatigue (2), and renal failure (2). One pt developed reversible cardiomyopathy (cycle 8) attributed to Bz. Calculated sensory/dysfunction (S/D) composite scores based on patient responses from the FACT/GOG-Ntx survey improved in 7 of 14 pts between cycles 1 and 4, were stable in 4 pts and worsened in only 3. On average, the S/D score accounted for 43% of each pt's total Ntx score at baseline, whereas it only accounted for 39% of the score after 4 cycles, and 45% after 8 cycles, indicating progressive disability from Bz-related PN was uncommon. As results of nerve conduction studies did not correlate well with reported symptoms or FACT/GOG-Ntx scores in stage 1 of the study, mandatory EMGs were discontinued in stage 2. Conclusions: MD-Bz shows promising activity in the treatment of AL, with 94% of pts in the first stage of this trial achieving HR (38% cHR) and evidence of OrR observed in 63%. Toxicity is manageable, but meds often require baseline or subsequent dose adjustment. A randomized study of MD +/- Bz in AL is planned. Disclosures: Zonder: Cephalon: Consultancy; Pfizer: Consultancy; Amgen: Consultancy; Millennium: Consultancy, Research Funding, Speaking CME Only, No PromotionalTalks; Celgene: Speaking CME only; no Promotional Talks. Off Label Use: Bortezomib is being used in the treatment of AL amyloidosis in this trial; it is currently approved for use as treatment of multiple myeloma.. Matous:Celgene: Honoraria, Speakers Bureau; Cephalon: Speakers Bureau. Janakiraman:Millennium: Honoraria, Research Funding. Mapara:Resolyx: Membership on an entity's Board of Directors or advisory committees, Research Funding; Cephalon: Membership on an entity's Board of Directors or advisory committees, My Wife: Suzanne Lentzsch, Research Funding; Celgene: Membership on an entity's Board of Directors or advisory committees, My wife: Suzanne Lentzsch, Research Funding; Sentium: Stocks. Gasparetto:Millennium: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees." @default.
• W2979667084 created "2019-10-18" @default.
• W2979667084 creator A5000233609 @default.
• W2979667084 creator A5002240997 @default.
• W2979667084 creator A5009017507 @default.
• W2979667084 creator A5010198450 @default.
• W2979667084 creator A5016774003 @default.
• W2979667084 creator A5020820919 @default.
• W2979667084 creator A5034791164 @default.
• W2979667084 creator A5041503485 @default.
• W2979667084 creator A5049638525 @default.
• W2979667084 creator A5049900530 @default.
• W2979667084 creator A5066180365 @default.
• W2979667084 creator A5068169827 @default.
• W2979667084 creator A5086510250 @default.
• W2979667084 creator A5090835650 @default.
• W2979667084 date "2009-11-20" @default.
• W2979667084 modified "2023-09-27" @default.
• W2979667084 title "Melphalan and Dexamethasone Plus Bortezomib Induces Hematologic and Organ Responses in AL-Amyloidosis with Tolerable Neurotoxicity." @default.
• W2979667084 doi "https://doi.org/10.1182/blood.v114.22.746.746" @default.
• W2979667084 hasPublicationYear "2009" @default.
• W2979667084 type Work @default.
• W2979667084 sameAs 2979667084 @default.
• W2979667084 citedByCount "9" @default.
• W2979667084 countsByYear W29796670842013 @default.
• W2979667084 countsByYear W29796670842014 @default.
• W2979667084 countsByYear W29796670842015 @default.
• W2979667084 countsByYear W29796670842016 @default.
• W2979667084 countsByYear W29796670842022 @default.
• W2979667084 crossrefType "journal-article" @default.
• W2979667084 hasAuthorship W2979667084A5000233609 @default.
• W2979667084 hasAuthorship W2979667084A5002240997 @default.
• W2979667084 hasAuthorship W2979667084A5009017507 @default.
• W2979667084 hasAuthorship W2979667084A5010198450 @default.
• W2979667084 hasAuthorship W2979667084A5016774003 @default.
• W2979667084 hasAuthorship W2979667084A5020820919 @default.
• W2979667084 hasAuthorship W2979667084A5034791164 @default.
• W2979667084 hasAuthorship W2979667084A5041503485 @default.
• W2979667084 hasAuthorship W2979667084A5049638525 @default.
• W2979667084 hasAuthorship W2979667084A5049900530 @default.
• W2979667084 hasAuthorship W2979667084A5066180365 @default.
• W2979667084 hasAuthorship W2979667084A5068169827 @default.
• W2979667084 hasAuthorship W2979667084A5086510250 @default.
• W2979667084 hasAuthorship W2979667084A5090835650 @default.
• W2979667084 hasConcept C126322002 @default.
• W2979667084 hasConcept C159654299 @default.
• W2979667084 hasConcept C203014093 @default.
• W2979667084 hasConcept C203092338 @default.
• W2979667084 hasConcept C2776063141 @default.
• W2979667084 hasConcept C2776364478 @default.
• W2979667084 hasConcept C2776694085 @default.
• W2979667084 hasConcept C2777478702 @default.
• W2979667084 hasConcept C2778684742 @default.
• W2979667084 hasConcept C2778720950 @default.
• W2979667084 hasConcept C2778822529 @default.
• W2979667084 hasConcept C2779551797 @default.
• W2979667084 hasConcept C2780401358 @default.
• W2979667084 hasConcept C31760486 @default.
• W2979667084 hasConcept C36394416 @default.
• W2979667084 hasConcept C535046627 @default.
• W2979667084 hasConcept C71924100 @default.
• W2979667084 hasConcept C90924648 @default.
• W2979667084 hasConceptScore W2979667084C126322002 @default.
• W2979667084 hasConceptScore W2979667084C159654299 @default.
• W2979667084 hasConceptScore W2979667084C203014093 @default.
• W2979667084 hasConceptScore W2979667084C203092338 @default.
• W2979667084 hasConceptScore W2979667084C2776063141 @default.
• W2979667084 hasConceptScore W2979667084C2776364478 @default.
• W2979667084 hasConceptScore W2979667084C2776694085 @default.
• W2979667084 hasConceptScore W2979667084C2777478702 @default.
• W2979667084 hasConceptScore W2979667084C2778684742 @default.
• W2979667084 hasConceptScore W2979667084C2778720950 @default.
• W2979667084 hasConceptScore W2979667084C2778822529 @default.
• W2979667084 hasConceptScore W2979667084C2779551797 @default.
• W2979667084 hasConceptScore W2979667084C2780401358 @default.
• W2979667084 hasConceptScore W2979667084C31760486 @default.
• W2979667084 hasConceptScore W2979667084C36394416 @default.
• W2979667084 hasConceptScore W2979667084C535046627 @default.
• W2979667084 hasConceptScore W2979667084C71924100 @default.
• W2979667084 hasConceptScore W2979667084C90924648 @default.
• W2979667084 hasIssue "22" @default.
• W2979667084 hasLocation W29796670841 @default.
• W2979667084 hasOpenAccess W2979667084 @default.
• W2979667084 hasPrimaryLocation W29796670841 @default.
• W2979667084 hasRelatedWork W1545720897 @default.
• W2979667084 hasRelatedWork W2025081120 @default.
• W2979667084 hasRelatedWork W2034642132 @default.
• W2979667084 hasRelatedWork W2154021003 @default.
• W2979667084 hasRelatedWork W2466365469 @default.
• W2979667084 hasRelatedWork W2513226303 @default.
• W2979667084 hasRelatedWork W2563502964 @default.
• W2979667084 hasRelatedWork W2605951469 @default.
• W2979667084 hasRelatedWork W4283760586 @default.
• W2979667084 hasRelatedWork W4310112940 @default.
• W2979667084 hasVolume "114" @default.
• W2979667084 isParatext "false" @default.
• W2979667084 isRetracted "false" @default.
• W2979667084 magId "2979667084" @default.

• next